Sharemaestro company-news research for Synopsys, Inc. (SNPS), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
Company news sentiment
SNPS news sentiment
Synopsys, Inc.
Company headlines compared by relevance, subject, source independence, tone and the market's completed price response.
An earlier measured reading is retained below: 50/100 from 13 articles on 13 Aug 03:08. Current source headlines are being refreshed without delaying this page.
Current company news
News confirmed by price
Constructive news tone is drawn from 7 fresh independent stories, including 7 company-specific items across 1 publishers.
Latest source headline OptimizeRx Corp. (OPRX) Q2 Earnings and Revenues Top Estimates finance.yahoo.com · 12 Aug 2026 21:40What supports the read
7 current stories are mapped specifically to SNPS.
Cross-story agreement is 93/100, indicating a comparatively coherent tape.
Constructive news tone is being confirmed by positive weekly price action.
What tempers the read
Only 1 publisher currently contribute to the measured read.
News history
Tone and story flow over 21 days
Evidence confidence
What supports the score
Confidence rises through sample depth, independent publishers, direct company relevance, freshness and agreement. A high or low tone score is not itself evidence of reliability.
Price context
Sentiment against the 26-week price path
Constructive news tone is being confirmed by positive weekly price action.
News subjects
What is shaping the score
Source mix
Where the evidence comes from
Recurring subjects
Subjects appearing most often
Earlier readings
How the score has changed
Source headlines
The news behind the score
Every row shows the public evidence used to understand the read. Direct company stories carry more weight than industry or sector context; duplicate coverage is consolidated before scoring.
OptimizeRx Corp. (OPRX) Q2 Earnings and Revenues Top Estimates
OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.24 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +45.46%. A quarter ago, it was expected that this company would post earnings of $0.01 per share when it actually produced earnings of $0.14, delivering a surprise of +1300%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. OptimizeRx, which belongs to the Z
- Published
- 12 Aug 2026 21:40
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
Can SNPS Leverage AI to Accelerate Chip Design and Drive Growth?
Synopsys SNPS is benefiting from the large AI infrastructure expansion, which is fueling semiconductor R&D, system-level design activity and demand for advanced AI computing capabilities. The company is integrating AI throughout its product portfolio to automate engineering processes, accelerate design cycles and enhance customer productivity. This is driving solid design wins, driven by a robust product portfolio. Synopsys is pursuing a multi-layered AI strategy. At the product level, the company has introduced XSO.ai to embed AI capabilities directly into its solutions. The second layer focu
- Published
- 12 Aug 2026 15:17
- Catalyst
- Balance sheet
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
Nvidia Will Be The World’s First $10 Trillion Company
AI is the most important tech advance in human history, and perhaps the greatest investment of all time. One only has to talk to the hundreds of millions of people who use it (or perhaps billions) and the army of companies around the world that say it will transform the way their employees work and pave a golden road to profits. It has also made untold numbers of people richer via ownership of its stock and the constellation of AI-related companies that surround it. Many of these have been helped by investments from Nvidia (NASDAQ: NVDA), or loans that will make them grow faster. If AI is the
- Published
- 12 Aug 2026 13:37
- Catalyst
- Balance sheet
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
Synopsys (SNPS) Bets Big On Agentic AI: Can The Stock Follow?
Synopsys (NASDAQ:SNPS) just showed off some of the most ambitious autonomous engineering software on the market, built alongside Nvidia (NASDAQ:NVDA), at the DAC Chips to Systems Conference on July 26. Yet the stock carries a roughly 12% year-to-date decline even as the company keeps gaining ground in the tools that design nearly every AI chip. That gap between what the business is doing and where the shares sit is the story here.Synopsys (SNPS) Bets Big On Agentic AI: Can The Stock Follow? Bull Case: Autonomous Agents Now Run The Whole Verification Cycle Synopsys unveiled a fully autonomous d
- Published
- 11 Aug 2026 20:30
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
Should You Hold or Fold SNPS Stock After a 20% Decline in 3 Months?
Synopsys, Inc. SNPS shares have plunged 19.8% in the past three months, underperforming the Zacks Computer - Software industry and the Zacks Computer and Technology sector's appreciation of 15.7% and 2%, respectively. SNPS Three-Month Performance ChartZacks Investment Research Image Source: Zacks Investment Research Despite the underperformance, SNPS stock is trading at a P/S multiple of 7.53x, much above the industry P/E multiple of 6.36x. This suggests a premium valuation further substantiated by a Zacks Value Score of D. SNPS Forward 12-Month Valuation ChartZacks Investment Research Image S
- Published
- 11 Aug 2026 14:39
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
Synopsys (SNPS) Just Locked Into Intel’s (INTC) Next Chip Node. What’s The Payoff?
Synopsys (NASDAQ:SNPS) just extended its grip on the leading edge of chipmaking. On July 27, at the DAC Chips to Systems Conference, the company said it has certified its AI-powered design software for Intel's (NASDAQ:INTC) upcoming 14A manufacturing process, building on flows it already runs in production on Intel's 18A and 18A-P nodes.Synopsys (SNPS) Just Locked Into Intel's (INTC) Next Chip Node. What's The Payoff? Bull Case: A Toolmaker Chipmakers Can't Design Without Synopsys's software and intellectual property sit underneath most of the advanced chips built today, and that is hard to di
- Published
- 10 Aug 2026 22:45
- Catalyst
- Earnings
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
Synopsys (SNPS) Unleashes Agentic AI Chip Design Tools Backed by Microsoft, AMD
Synopsys (NASDAQ:SNPS) just handed AMD (NASDAQ:AMD) and Microsoft (NASDAQ:MSFT) a new way to design chips: let AI agents do more of the work. On July 27, Synopsys unveiled autonomous agentic AI workflows built with Microsoft and already being evaluated by AMD, aimed at cutting the time it takes to turn a chip specification into working silicon. The announcement lands as investors weigh whether Synopsys deserves its premium for owning so much of the AI buildout's tooling.Synopsys (SNPS) Unleashes Agentic AI Chip Design Tools Backed by Microsoft, AMD Bull Case: Agents Doing The Engineering, Not
- Published
- 10 Aug 2026 14:39
- Catalyst
- Guidance
- Evidence role
- Direct company coverage
- Duplicates
- 1 consolidated
How the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean a balanced tape or that direction has been withheld for insufficient evidence; the status label distinguishes them.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
The page describes completed evidence available at the stated time. It is research context, not a forecast, recommendation, target or execution instruction.